News
09-21-2012, 12:11 AM
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its completed Phase 3 Lymphoseek studies in breast cancer and melanoma are being presented at the 32nd Congress of the European Society of Surgical Oncology (ESSO) in Valencia, Spain, from September 19-21, 2012.
More... (http://www.news-medical.net/news/20120921/Data-from-Navideae28099s-Lymphoseek-Phase-3-studies-on-solid-tumors-to-be-presented-at-ESSO.aspx)
More... (http://www.news-medical.net/news/20120921/Data-from-Navideae28099s-Lymphoseek-Phase-3-studies-on-solid-tumors-to-be-presented-at-ESSO.aspx)